Literature DB >> 16870915

Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.

David A Fiellin1, Michael V Pantalon, Marek C Chawarski, Brent A Moore, Lynn E Sullivan, Patrick G O'Connor, Richard S Schottenfeld.   

Abstract

BACKGROUND: The optimal level of counseling and frequency of attendance for medication distribution has not been established for the primary care, office-based buprenorphine-naloxone treatment of opioid dependence.
METHODS: We conducted a 24-week randomized, controlled clinical trial with 166 patients assigned to one of three treatments: standard medical management and either once-weekly or thrice-weekly medication dispensing or enhanced medical management and thrice-weekly medication dispensing. Standard medical management was brief, manual-guided, medically focused counseling; enhanced management was similar, but each session was extended. The primary outcomes were the self-reported frequency of illicit opioid use, the percentage of opioid-negative urine specimens, and the maximum number of consecutive weeks of abstinence from illicit opioids.
RESULTS: The three treatments had similar efficacies with respect to the mean percentage of opioid-negative urine specimens (standard medical management and once-weekly medication dispensing, 44 percent; standard medical management and thrice-weekly medication dispensing, 40 percent; and enhanced medical management and thrice-weekly medication dispensing, 40 percent; P=0.82) and the maximum number of consecutive weeks during which patients were abstinent from illicit opioids. All three treatments were associated with significant reductions from baseline in the frequency of illicit opioid use, but there were no significant differences among the treatments. The proportion of patients remaining in the study at 24 weeks did not differ significantly among the patients receiving standard medical management and once-weekly medication dispensing (48 percent) or thrice-weekly medication dispensing (43 percent) or enhanced medical management and thrice-weekly medication dispensing (39 percent) (P=0.64). Adherence to buprenorphine-naloxone treatment varied; increased adherence was associated with improved treatment outcomes.
CONCLUSIONS: Among patients receiving buprenorphine-naloxone in primary care for opioid dependence, the efficacy of brief weekly counseling and once-weekly medication dispensing did not differ significantly from that of extended weekly counseling and thrice-weekly dispensing. Strategies to improve buprenorphine-naloxone adherence are needed. (ClinicalTrials.gov number, NCT00023283 [ClinicalTrials.gov].). Copyright 2006 Massachusetts Medical Society.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16870915     DOI: 10.1056/NEJMoa055255

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  143 in total

1.  Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.

Authors:  Franco Montesano; Domenico Zaccone; Egidio Battaglia; Felice Genco; Vincenzo Mellace
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

2.  Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.

Authors:  Patrizia Amato
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

3.  Improving temporal efficiency of outpatient buprenorphine induction.

Authors:  Erik W Gunderson; Frances R Levin; Margaret M Rombone; Suzanne K Vosburg; Herbert D Kleber
Journal:  Am J Addict       Date:  2011-07-18

4.  Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection.

Authors:  Jeanette M Tetrault; Janet P Tate; E Jennifer Edelman; Adam J Gordon; Vincent Lo Re; Joseph K Lim; David Rimland; Joseph Goulet; Stephen Crystal; Julie R Gaither; Cynthia L Gibert; Maria C Rodriguez-Barradas; Lynn E Fiellin; Kendall Bryant; Amy C Justice; David A Fiellin
Journal:  J Subst Abuse Treat       Date:  2016-06-06

5.  Medication-Assisted Treatment Use Among Pregnant Women With Opioid Use Disorder.

Authors:  Elizabeth E Krans; Joo Yeon Kim; Alton Everette James; David Kelley; Marian P Jarlenski
Journal:  Obstet Gynecol       Date:  2019-05       Impact factor: 7.661

6.  Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial.

Authors:  Gail D'Onofrio; Patrick G O'Connor; Michael V Pantalon; Marek C Chawarski; Susan H Busch; Patricia H Owens; Steven L Bernstein; David A Fiellin
Journal:  JAMA       Date:  2015-04-28       Impact factor: 56.272

7.  Use of hospital-based services among young adults with behavioral health diagnoses before and after health insurance expansions.

Authors:  Ellen Meara; Ezra Golberstein; Rebecca Zaha; Shelly F Greenfield; William R Beardslee; Susan H Busch
Journal:  JAMA Psychiatry       Date:  2014-04       Impact factor: 21.596

8.  Coercion into addiction treatment and subsequent substance use patterns among people who use illicit drugs in Vancouver, Canada.

Authors:  Andreas Pilarinos; Brittany Barker; Ekaterina Nosova; M-J Milloy; Kanna Hayashi; Evan Wood; Thomas Kerr; Kora DeBeck
Journal:  Addiction       Date:  2019-09-06       Impact factor: 6.526

9.  A comparison of buprenorphine and psychosocial treatment outcomes in psychosocial and medical settings.

Authors:  Ned J Presnall; D A Patterson Silver Wolf; Derek S Brown; Sara Beeler-Stinn; Richard A Grucza
Journal:  J Subst Abuse Treat       Date:  2019-06-15

Review 10.  Moving HIV pre-exposure prophylaxis into clinical settings: lessons from buprenorphine.

Authors:  E Jennifer Edelman; David A Fiellin
Journal:  Am J Prev Med       Date:  2013-01       Impact factor: 5.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.